Caidya Appoints Dr. Bin Peng as Chair of its China Scientific Advisory Board
RALEIGH, N.C.; September 19, 2025 – Caidya, a leading global contract research organization (CRO), recently announced the official appointment of Dr. Bin Peng as Chair of its China Scientific Advisory Board.
Dr. Peng will lead Caidya’s China Scientific Advisory Board, integrating expert resources and subject matter insights to promote high-level scientific and medical exchanges. By facilitating collaboration and knowledge sharing among top experts, the committee will strive to address complex clinical and scientific challenges, stimulate innovative ideas, explore new strategic opportunities, further enhance Caidya’s end-to-end clinical development capabilities, and expand its service offerings in the field of drug research and development.
Dr. Peng brings more than 30 years of extensive experience in clinical development and clinical pharmacology. He has held key management and technical leadership positions at global pharmaceutical leaders including Novartis (Switzerland) and GSK (U.S.), spearheading and contributing to numerous blockbuster drug development programs with remarkable achievements. Notably, he played a pivotal role in the development of the revolutionary targeted cancer therapy Glivec® and has published numerous high-impact clinical publications in international renowned academic journals such as The New England Journal of Medicine. Dr. Peng earned his bachelor’s and master’s degrees from the Medical School of Sun Yat-sen University in Guangzhou, and his PhD in Clinical Pharmacology from Newcastle University, UK. He completed postdoctoral research at the University of Manchester under world renowned clinical pharmacologist Professor Malcolm Rowland. He previously served as Chief Medical Officer of EpimAb Biotherapeutics (Shanghai), and now is the Guest Professor of Clinical Research Institute, Peking University and a Medical Advisor for Shanghai Ennovabio.
Dr. Jie Li, General Manager of Caidya China, stated, “We are honored to welcome Dr. Peng as Chair of Caidya’s China Scientific Advisory Board. He is a highly authoritative and influential expert in clinical research. Under his leadership, we are confident that the Advisory Board will inject exceptional scientific insights and forward-looking strategic vision into our scientific development and strategic planning.
“I am very delighted to join Caidya’s China Scientific Advisory Board,” said Dr. Bin Peng. “I look forward to working closely with the experts on the Advisory Board and our biopharma partners to deliver patient-centered, high-quality integrated clinical trial solutions. Together, we can help bring more sustainable innovative therapies to patients.”
About Caidya
Caidya is a global, full-service contract research organization (CRO) built for biopharma innovators developing life-changing therapies. Conducting studies in over 50 countries and a strong presence across North America, Europe, and Asia-Pacific, Caidya delivers a superior customer experience through personalized solutions that span the full clinical development lifecycle. From pre-IND strategy through study closeout and post-marketing, Caidya brings therapeutic expertise, operational agility, and an ownership mindset to every partnership. Specializing in complex, multi-regional trials across oncology, hematology, rare disease, pediatrics, cardiovascular, and more, Caidya consistently delivers on timelines and outcomes. Working shoulder to shoulder as partners, we bring expertise relevant to your study, agility to navigate complex trials, and global access to patients, yielding the high-quality data you need to make informed decisions – for today, and tomorrow.
MEDIA CONTACT:
Roger Boutin
VP, Corporate Marketing, Caidya
[email protected]